Clinical trials
ILD clinical trials
Below are recruiting ild clinical trials, each written for real people, not researchers. We’re tracking 61 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07482917Recruiting
Streamlining the diagnosis of interstitial lung disease
This study is testing a new way to speed up the diagnosis of interstitial lung disease (a group of lung scarring conditions). If you have symptoms or scan findings that suggest ILD but haven't been fully diagnosed yet, this trial may help you get a faster, clearer answer.
Granollers, BarcelonaAges 18 years+ - NCT07486206Recruiting
Optimizing follow-up for interstitial lung disease
This trial tests a new way to organize follow-up visits for people with interstitial lung disease (a group of lung conditions). It aims to make care simpler and more effective for patients who are already on treatment.
Granollers, BarcelonaAges 18 years+ - NCT06644144Recruiting
P4O2: A study for people with lung scarring
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
Amsterdam, North HollandAges 18–80 - NCT07457502Recruiting
Home environment and lung disease progression study
This study looks at whether things in your home might affect how quickly your lung disease gets worse. You and a matched group will be followed to see how your home environment impacts your lung health.
Paris, ParisAges 18 years+ - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06189495RecruitingPhase 2
Study of Genakumab for lung scarring from connective tissue disease
This study tests a new injected medication (Genakumab) for people with connective tissue disease-related lung scarring. It aims to see if it helps stabilize or improve lung function safely.
Beijing, Beijing MunicipalityAges 18–75 - NCT06998706RecruitingPhase 1
Testing patient's own lung stem cells for ILD
This study tests whether a patient's own lung stem cells can be used to repair damaged lungs in people with interstitial lung disease. It is an early-stage trial to see if the treatment is safe and may help improve breathing.
Qionghai, HainanAges 40–75 - NCT03478826Recruiting
Donate blood samples for a lung disease research biobank
This study builds a “biobank,” a storage of blood and related samples, from people with lung interstitial lung diseases or other lung scarring diseases. Your samples help researchers study these conditions and improve future care.
Rochester, MinnesotaAges 18 years+ - NCT05086432Recruiting
Test sputum-guided care to reduce cough in lung scarring
This study uses analysis of mucus (sputum) to guide treatment with the goal of reducing long-lasting cough in adults with interstitial lung disease (ILD). You may be asked to provide sputum samples and may receive treatment decisions based on those results.
Hamilton, OntarioAges 18 years+ - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Los Angeles, CaliforniaAges 18 years+ - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Birmingham, AlabamaAges 18 years+ - NCT06577753Recruiting
Chinese medicine study for interstitial lung disease
This study follows people with interstitial lung disease to learn more about how Chinese medicine can help. If you have ILD and are 18 or older, you may be able to join.
Zhengzhou, HenanAges 18 years+ - NCT06919380RecruitingPhase 1
Mist from stem cell byproducts for autoimmune lung disease
This study tests a new type of treatment using a mist (nebulized) made from stem cell byproducts to see if it can safely help people with a rare autoimmune lung disease. It is for patients with anti-MDA5 positive dermatomyositis who have a fast-progressing lung condition.
Guangzhou, GuangdongAges 18–75 - NCT07300696Recruiting
MRI to track lung disease changes in ILD
This study uses MRI scans to monitor how lung scarring changes over time in people with certain types of interstitial lung disease (ILD), like idiopathic pulmonary fibrosis (IPF). The goal is to see if MRI can be a helpful tool for tracking the disease without needing as many CT scans.
HeidelbergAges 18 years+ - NCT07333183RecruitingPhase 2
Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Kissimmee, FloridaAges 18–85 - NCT07179380RecruitingPhase 3
A study of an inhaled drug for lung disease with high blood pressure
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
Los Angeles, CaliforniaAges 18 years+ - NCT07234032RecruitingPhase 3
Long-term follow-up study of TPIP for PH-ILD
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Naples, FloridaAges 18 years+ - NCT06475781RecruitingPhase 2
Study of mirivadelgat for pulmonary hypertension with interstitial lung disease
This study tests a new medication called mirivadelgat for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The goal is to see if it can help improve symptoms and slow the progression of the disease.
Hualien City, TaiwanAges 18–85 - NCT07175038RecruitingPhase 2
Study of a new pill for pulmonary hypertension
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Phoenix, ArizonaAges 18–80 - NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT05838183Recruiting
Test treatment in people with lung disease and sleep apnea
This trial is studying how a treatment may work for adults who have interstitial lung disease or obstructive sleep apnea. It likely involves sleep testing so the team can measure breathing and sleep patterns.
TianjinAges 18–80 - NCT06911632Recruiting
AI-assisted check for pulmonary hypertension in interstitial lung disease
This study uses an AI tool to help doctors decide if you should be tested for pulmonary hypertension (high blood pressure in the lungs), which can be a complication of interstitial lung disease. If the tool suggests you might have it, you may get an echocardiogram (an ultrasound of the heart) and a right heart catheterization (a test to measure pressure in the heart) to find out for sure.
Birmingham, AlabamaAges 18 years+ - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT07512687Recruiting
Portable Oxygen During Daily Activity for Lung Disease
This study tests whether using portable oxygen during everyday activities helps people with certain lung diseases (like pulmonary fibrosis or COPD) who only experience low oxygen levels when moving around. Researchers want to see if a portable oxygen device improves how well participants can function and feel during daily life.
Buffalo, New YorkAges 18–85
Hear when a new ILD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ild?
- Yes. Clin2 currently lists 61 recruiting ild studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ild trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ild trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.